Your browser doesn't support javascript.
Long-term outcomes after NeuroCOVID: A 6-month follow-up study on 60 patients.
Chaumont, H; Meppiel, E; Roze, E; Tressières, B; de Broucker, T; Lannuzel, A.
  • Chaumont H; Service de neurologie, Centre hospitalier universitaire de la Guadeloupe, Pointe-à-Pitre/Abymes, Guadeloupe; Faculté de Médecine de l'université des Antilles, Pointe-à-Pitre, Guadeloupe; Sorbonne Université, Institut national de la Santé et de la Recherche médicale, U 1127, CNRS, Unité Mixte de Rech
  • Meppiel E; Service de Neurologie, Centre hospitalier de Saint-Denis, Hôpital Delafontaine, Saint-Denis, France.
  • Roze E; Sorbonne Université, Institut national de la Santé et de la Recherche médicale, U 1127, CNRS, Unité Mixte de Recherche (UMR) 7225, Institut du Cerveau, Paris, France; Département de Neurologie, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.
  • Tressières B; Centre d'investigation Clinique Antilles Guyane, Inserm CIC 1424, Pointe-à-Pitre, Guadeloupe.
  • de Broucker T; Service de Neurologie, Centre hospitalier de Saint-Denis, Hôpital Delafontaine, Saint-Denis, France.
  • Lannuzel A; Service de neurologie, Centre hospitalier universitaire de la Guadeloupe, Pointe-à-Pitre/Abymes, Guadeloupe; Faculté de Médecine de l'université des Antilles, Pointe-à-Pitre, Guadeloupe; Sorbonne Université, Institut national de la Santé et de la Recherche médicale, U 1127, CNRS, Unité Mixte de Rech
Rev Neurol (Paris) ; 178(1-2): 137-143, 2022.
Article in English | MEDLINE | ID: covidwho-1611935
ABSTRACT
BACKGROUND AND

PURPOSE:

Long-term outcomes after neurological manifestations due to COVID-19 are poorly known. The aim of our study was to evaluate the functional outcome and identify the risk factors of neurologic sequelae after COVID-19 associated with neurological manifestations (NeuroCOVID).

METHODS:

We conducted a multi-center observational study six months after the acute neurological symptoms in patients from the French NeuroCOVID hospital-based registry.

RESULTS:

We obtained data on 60 patients. NeuroCOVID had a negative impact on the quality of life (QoL) of 49% of patients. Age was a predictor of residual QoL impairment (OR 1.06, 95% CI 1.01-1.13, p=0.026). At six months, a significant residual disability was found in 51.7% of patients, and impaired cognition in 68.9% of cases. The main persistent neuropsychiatric manifestations were a persistent smell/taste disorder in 45% of patients, memory complaints in 34% of patients, anxiety or depression in 32% of patients.

CONCLUSIONS:

NeuroCOVID likely carries a high risk of long-term neuropsychiatric disability. Long-term care and special attention should be given to COVID-19 patients, especially if they had neurological manifestations during acute infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Nervous System Diseases Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Rev Neurol (Paris) Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Nervous System Diseases Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Rev Neurol (Paris) Year: 2022 Document Type: Article